
Speaker:
Cristovam Scapulatempo Neto, MD, PhD - Medical Director of Pathology and Genetics, Diagnósticos da América S.A.
Comprehensive genomic profiling (CGP) is transforming precision oncology by enabling more precise and personalized cancer care. However, as demand for testing grows, many clinical laboratories face significant operational hurdles—from fragmented and rigid analysis workflows to long turnaround times. Decentralized testing enables laboratories to perform large-scale molecular analysis in-house, retain full control of their data, and streamline workflows to accelerate time to results.
In this Inside Precision Medicine webinar, Cristovam Scapulatempo Neto, MD, PhD, will explore how a decentralized, tech-agnostic approach can help laboratories expand their CGP capabilities. Using SOPHiA DDM™ for CGP by SOPHiA GENETICS as an example, he will discuss how this advanced analytical solution, which is designed to be compatible with a wide range of sequencing platforms, helps laboratories streamline processes and scale testing without compromising accuracy. The webinar will provide insights into what the solution offers, including:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.